We now know Tome’s gene editing target

Off Biotech, biotechnology, Business, drug development, drug prices, drug pricing, FDA, finance, genetics, Health, Human Health, Life Sciences, Medicine, Pharma, Pharmaceuticals, policy, research, Science and Research, The Readout

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Hello! Today we learn whether AI might help hasten the development of n-of-1 therapies (hint: not yet), explore why the FDA hasn’t offered Orange Book guidance on drug-device combinations, and talk about CRISPR. A lot.

Read the rest…

Read Original Article: We now know Tome’s gene editing target »

About The Author